Please assess the completion status of the following clinical trial:

Trial Title: Chlortalidone and Bumetanide in Advanced Chronic Kidney Disease: HEBE-CKD Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* glomerular filtration rate less than 30 ml / min / 1.73m~* Without replacement therapy (dialysis or hemodialysis)~* Volume overload~* At least 100 ml per day of residual diuresis~* Use of a loop diuretic for at least one month~Exclusion Criteria:~* Allergies known to diuretics~* Patients with severe infections~* Patients with hemodynamic instability~* Amputees~* Patients with cognitive impairment~* Patients with acute renal failure~* Patients with graft loss

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): This group will receive 3 milligrams of bumetanide per day for a week plus placebo (starch) that will simulate the chlorthalidone dose of the treatment group. In case the dose is well tolerated, the dose of bumetanide will be increased to 4 milligrams per day.
- Treatment grup (Type: EXPERIMENTAL): This group will receive 3 milligrams of bumetanide plus 50 milligrams of chlorthalidone per day, for a week. If the dose is well tolerated, it will be increased to 4 milligrams of bumetanide and 100 milligrams of chlorthalidone per day.

Based on this trial design, predict the completion outcome and termination type (if applicable).